

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 7

Date: 18/11/2022

Location: Virtually via Zoom

Minutes: Confirmed

Committee members present:		
Alison Cameron (Chair)		(Present for notes 1 – 8)
Victoria Barber		(Present for notes 1 – 8)
Adam Brentnall		(Present for notes 1 – 8)
Judith Hayward		(Present for notes 1 – 8)
Tracie Miles		(Present for notes 3 – 8)
Davina Moses		(Present for notes 1 – 8)
Fiona Robb		(Present for notes 1 – 8)
Adam Rosenthal		(Present for notes 1 – 8)
Lucy Side		(Present for notes 1 – 8)
Joanne Stanford		(Present for notes 1 – 8)
Mark Davies		(Present for notes 1 – 8)
Britta Stordal		(Present for notes 1 – 8)
Kevin Monahan		(Present for notes 1 – 8)

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Katriona O'Donoghue	Systematic Reviewer	(Present for note 1)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Emma Clegg	Information Scientist	(Present for notes 1 – 8)
Nick Staples	Guideline Commissioning Manager	(Present for notes 1 – 8)
Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 8)

Dan Auker-Howlett (Observer)	Policy and Project Manager Medicines Policy & Analysis Unit Commercial Medicines Directorate, NHS England	(Present for notes 1 – 8)
Apologies:		
Rebecca Bowen	Committee member	
Melanie Davies	Committee member	
Glenn McCluggage	Committee member	
Vishakha Tripathi	Committee member	
Steve Pilling	Clinical Advisor	
Neil Ryan	Clinical Fellow	
Tara Chernick	Adoption and Implementation Manager	
Not in attendance		
Ranjit Manchanda	Topic Advisor	
Gareth Evans	Committee member	

1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members and attendees to the 7th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared as noted below. The chair confirmed that Ranjit Manchanda and Gareth Evans were excluded from attending the whole committee meeting due to previously declared interest precluding the members from participating.

Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Britta	Committee	Direct	NICE	Novemb	Ongoing	12/12/202	Declare

Stordal	member	non-financial professional and personal interest	Technology Appraisal Committee	er 2022	g	2	and participate. Agreed by GL and NICE CA at recruitment – December 2022 Rationale: This Technology Appraisal is not directly related to the scope of the guideline.
---------	--------	--	--------------------------------	---------	---	---	--

3. Minutes of the last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.

4. Morning presentations

KO gave an update on review question 1.1

The Chair introduced Nathan Bromham, Senior Systematic Reviewer and Laura Berg, Systematic Reviewer who presented the following evidence review questions:

4.4: At what carrier probability should women with ovarian cancer (with or without breast cancer) be offered genetic testing?

4.1: At what carrier probability should people with a family history of ovarian cancer (with or without breast cancer) be offered genetic testing?

4.2: On the basis of what carrier probability or criteria should a person with a personal or family history suggestive of a clinically defined syndrome associated with an increased risk of ovarian cancer (for example Peutz-Jeghers syndrome) be offered genetic testing?

Eric Slade, Senior Health Economist, provided an update on the economics for 4.1 and 4.4.

Alison Cameron, Committee Chair, Judith Hayward, Topic Group Lead for 4.4, led the committee in drafting recommendation for review question 4.4

5. Lay member forum

Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.

6. Afternoon presentations

Alison Cameron, Committee Chair, and Kevin Monahan, Topic Group Lead for 4.2, led on drafting recommendations for review question 4.2.

Alison Cameron, Committee Chair, and Lucy Side, Topic Group Lead 4.1 led on drafting recommendations for review question 4.1.

Nathan Bromham, Senior Systematic Reviewer, who provided an update on review questions 3.1: What are the optimal methods of assessing the probability of having a pathogenic variant associated with familial ovarian cancer? and 3.2: What are the optimal methods of assessing the absolute risk of ovarian cancer?

7. Questions and discussion

The committee discussed:

- The evidence presented for evidence review questions 4.1, 4.2 and 4.4
- Edits to drafted recommendations and the addition of recommendations
- Updates and work progress on review questions 3.1 and 3.2

8. Any other business and summary of actions

Katharina Dworzynski summarised the actions and confirmed the topics for the next meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

Date of next meeting: 13/12/2022

Location of next meeting: Via Zoom.